International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

PreScription: Compounding with Cannabidiol

Author(s): Allen Loyd V Jr

Issue: Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Page(s): 92

PreScription: Compounding with Cannabidiol Page 1

Download in electronic PDF format for $75

Abstract:

Related Keywords: CBD, cannabidiol, cannabinoids, US Food and Drug Administration, FDA, Cannabis sativa L., epilepsy, United States Pharmacopeia, USP, adverse effects

Related Categories: LEGAL, ADVERSE DRUG EVENTS

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
PreScription: Compounding with Cannabidiol Allen Loyd V Jr	Mar/Apr 2019 Pg. 92
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1 Allen Loyd V Jr	Mar/Apr 2020 Pg. 92
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2 Allen Loyd V Jr	May/Jun 2020 Pg. 180
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1 Martin Matt	Sep/Oct 2018 Pg. 401-404
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
PreScription: The Past (-->2020), The Present, and The Future (2021-->) Allen Loyd V Jr	Mar/Apr 2021 Pg. 92
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice Kelley Brian	Mar/Apr 2021 Pg. 115-124
PreScription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800> Allen Loyd V Jr	Sep/Oct 2021 Pg. 356
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Allen Loyd V Jr	Nov/Dec 2023 Pg. 474-481
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
Return to Top